Characterisation of antibody responses induced by BCG and other TB vaccines to inform future vaccine design
Tuberculosis (TB) remains a pressing global health challenge. The focus of TB vaccine research traditionally centres on either enhancing BCG's efficacy or identifying a suit-able alternative. Within this context, antibody responses, a potentially relevant corre-late of protection, are inadequat...
Príomhchruthaitheoir: | Peralta Alvarez, MP |
---|---|
Rannpháirtithe: | Tanner, R |
Formáid: | Tráchtas |
Teanga: | English |
Foilsithe / Cruthaithe: |
2023
|
Ábhair: |
Míreanna comhchosúla
-
Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
de réir: Marco Polo Peralta Alvarez, et al.
Foilsithe / Cruthaithe: (2024-05-01) -
Need for BCG Vaccination to Prevent TB in High-Incidence Countries and Populations
de réir: Shalini Pooransingh, et al.
Foilsithe / Cruthaithe: (2020-03-01) -
Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine
de réir: Nancy Gupta, et al.
Foilsithe / Cruthaithe: (2018-10-01) -
Commentary: Bettering BCG: a tough task for a TB vaccine?
de réir: Brahm S. Srivastava, et al.
Foilsithe / Cruthaithe: (2019-09-01) -
Mantoux test results and BCG vaccination status in TB-exposed children
de réir: Fadilah Harahap, et al.
Foilsithe / Cruthaithe: (2015-03-01)